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Dabigatran Reversal with Idarucizumab
To the Editor: Data provided by Pollack and
colleagues (Aug. 3 issue)1 suggest a dissociation
between the normalization of the coagulation
profile and the establishment of effective hemostasis after the administration of idarucizumab
in patients with uncontrolled bleeding. The median
time to the cessation of bleeding was 2.5 hours
among patients with nonintracranial hemorrhage.
In analyses reported separately, the median time to
the cessation of bleeding was 3.5 hours among patients with gastrointestinal bleeding and 4.5 hours
among those with nonintracranial and nongastrointestinal bleeding.2 The median time to the cessation of bleeding was 11.4 hours when intracranial hemorrhage was included in the analysis
involving patients with serious bleeding.3 Should
clinicians rely solely on idarucizumab and hope
that their patients do not die from uncontrolled
hemorrhage while waiting for hemostasis to be
established? A reasonable approach would be to
administer blood-component therapy (e.g., prothrombin complex concentrate and activated prothrombin complex concentrate) — a bridge between the normalization of the coagulation profile
and the establishment of hemostasis, according
to in vitro and preclinical data4,5 — in addition to
idarucizumab. It can be reasonably argued that
the establishment of effective hemostasis with
blood-component and idarucizumab therapy outweighs the risk of thrombotic adverse events
among patients with serious hemorrhaging. The
1690
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effectiveness and need for further blood-component and idarucizumab therapy may be assessed
by serial clinical assessments and a serial profile
of clotting times.
Luke Yip, M.D.
Rocky Mountain Poison and Drug Center
Denver, CO
luke.yip@rmpdc.org
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To the Editor: In 2015, an interim analysis involving 51 patients with acute bleeding who had
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received idarucizumab for dabigatran reversal
was published in the Journal.1 That article reported a median time to the cessation of bleeding of
11.4 hours among 35 of 51 patients (69%). At a
2016 American Heart Association conference,
data from 298 patients with acute bleeding were
presented. The median time to the cessation of
bleeding was reported in 158 patients (53%) as
3.5 hours among 97 patients with gastrointestinal bleeding and as 4.5 hours among 61 patients
with nongastrointestinal and nonintracranial
bleeding.2 Finally, in the full cohort analysis involving 503 patients, of the 301 patients with
acute bleeding, the median time to the cessation
of bleeding is reported as 2.5 hours but was analyzed in only 134 patients (45%).
We are concerned that selective reporting bias
influenced the reporting of this important secondary clinical outcome, because each subsequent
analysis reduced the fraction of the cohort included in this calculation (from 69% to 53% to
45%) while increasing the apparent clinical efficacy. We ask the authors to provide substantially
more robust reporting of these data for the full
cohort to better illuminate these evolving results.
Ryan P. Radecki, M.D.
University of Texas Health Science Center at Houston
Houston, TX

Thomas G. DeLoughery, M.D.
Oregon Health and Science University
Portland, OR
delought@ohsu.edu

gatran concentration. There is some evidence,1,2
and some degree of consensus,3 that the aPTT
(the only measurement available in emergency
situations in most centers) is too insensitive to estimate dabigatran concentration, but little of the
evidence has been gathered in the context of
urgent reversal and not in a prespecified peak–
trough fashion. Therefore, an analysis of this
correlation in the more than 500 patients who
were included in the RE-VERSE AD study would
be valuable. Given that urgent reversal is a rare
need, this information is not likely to be obtained
otherwise. Were the aPTT results not reported or
analyzed because of the already available evidence that aPTT should not be used? Would the
authors provide sensitivity and specificity and
predictive values for aPTT to detect therapeutic
dabigatran concentrations?
Marc Sorigue, M.D.
Institut Català d’Oncologia
Badalona, Spain
msorigue@iconcologia.net
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The authors reply: Idarucizumab is licensed for
dabigatran reversal in patients who have serious
bleeding or are undergoing urgent surgery. Yip
and Deng speculate that in addition to idarucizu
mab, prohemostatic agents such as prothrombin
complex concentrate or recombinant activated
factor VII should be administered to hasten hemostasis in dabigatran-treated patients with severe
hemorrhage. Few of the patients who were enrolled in the RE-VERSE AD study received prohemostatic agents in addition to idarucizumab,
so the efficacy and safety of such therapy cannot
be assessed.1 However, prohemostatic agents are
unlikely to be of benefit unless there is associated coagulopathy, because idarucizumab reverses
the anticoagulant effects of dabigatran within
minutes. Furthermore, prohemostatic agents may
increase the risk of thrombosis.

DOI: 10.1056/NEJMc1711337

To the Editor: Pollack et al. report the anticipated final results of the RE-VERSE AD study
regarding the use of idarucizumab to reverse the
effects of dabigatran in patients who have lifethreatening hemorrhage or who are undergoing
emergency surgery. However, the authors do not
report the correlation between the activated partial-thromboplastin time (aPTT) and the diluted
thrombin time, the ecarin clotting time, or dabin engl j med 377;17
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Radecki and DeLoughery are concerned about
the divergence in the median times to the cessation of bleeding that were reported in the interim
and final analyses of the data from the RE-VERSE
AD study. For patients with serious bleeding, the
protocol mandated the assessment of the time to
the cessation of bleeding up to 24 hours after the
administration of the first vial of idarucizumab.1
The longer time that was reported in the interim
analyses2,3 reflects the inclusion of patients with
recorded times exceeding 24 hours and patients
with intracranial hemorrhage, many of whom
did not undergo repeat brain imaging until several days after admission. To adhere to the perprotocol definition, these patients were excluded
in the final analysis, which explains the shorter
times to the cessation of bleeding. We agree that
their exclusion limits the generalizability of the
findings to this subgroup. Therefore, postmarketing data are needed to better assess the effect
of idarucizumab on the time to the cessation of
bleeding in these patients.4
Sorigue correctly points out that the diluted
thrombin time or ecarin clotting time is not available in many hospitals, and he requests information on the correlation between the aPTT and
these tests. This information is provided in Figure 1D of our article and in Figure S2 in the
Supplementary Appendix (available with the full
text of our article at NEJM.org), which show that
there is good correlation between the aPTT as
measured in the central laboratory and the more
specialized tests. Therefore, these data provide
preliminary evidence that the aPTT can also be
used to monitor dabigatran reversal, provided
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that the test is performed with a reagent that is
sensitive to the anticoagulant effects of dabigatran. In the RE-VERSE AD study, the central laboratory used the CK-Prest reagent (Diagnostica
Stago). It is important to point out, however, that
coagulation testing before the administration of
idarucizumab is not essential in patients who
have life-threatening bleeding or in whom urgent
surgery is indicated.
Charles V. Pollack, Jr., M.D.
Thomas Jefferson University
Philadelphia, PA
charles.pollack@jefferson.edu
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IgG Endopeptidase in Highly Sensitized Patients Undergoing
Transplantation
To the Editor: The study conducted by Jordan
et al. (Aug. 3 issue)1 included a low-risk population (2 patients did not have donor-specific antibodies) and pretreatment class I donor-specific
antibody levels (the major risk factor for antibody-mediated rejection) were modest (mean [±SD]
fluorescence intensity, 5660±2364), yet a high
rate of rejection occurred (10 of 22 patients [45%]
with donor-specific antibodies). These data raise
serious concerns for higher-risk patients.
1692
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A high rate of delayed graft function (77% of
patients) occurred in the U.S. cohort, despite a
short cold ischemia time (mean, 19.9±5.2 hours).
Did kidney biopsies that were performed in patients with delayed graft function reveal endothelial or renal tubular injury? Since donor-specific
antibodies induce pathogenic signaling properties in endothelium,2 it is important to determine
whether F(ab′)2 donor-specific antibody fragments retain signaling properties, particularly if
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